Wednesday, July 8, 2026

biotech · Recurrent Plasma Cell Myeloma · Anal Cancer Metastatic · ONCY

Oncolytics Biotech

Oncolytics Biotech is a biotech organization headquartered in San Diego, USA. It trades on NYSE under ticker ONCY. Primary therapeutic focus areas include Recurrent Plasma Cell Myeloma, Anal Cancer Metastatic, Ras-mutate

4350 Executive Dr, 325, San Diego, California 92121, US HQ
1998 Founded
46 Employees
Public company Type
ONCY · NYSE Ticker
Company details
Status
Public
HQ
4350 Executive Dr, 325, San Diego, California 92121, US
Founded
1998
Employees
46
Programs
23
Drugs
14
Patents
66
Clinical program

Carfilzomib

Phase 1 · small molecule · Recurrent Plasma Cell Myeloma

Carfilzomib for Recurrent Plasma Cell Myeloma is a Phase 1 program (small_molecule) at ONCOLYTICS BIOTECH INC with 1 ClinicalTrials.gov record(s).

← All ONCOLYTICS BIOTECH INC projects Phase 1 small molecule completed

Internal code IRB00104234

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
ONCOLYTICS BIOTECH INC
Phase
Phase 1
Modality
small_molecule
Indication
Recurrent Plasma Cell Myeloma
Status
completed
Trials
1